DOD prostate cancer research program FY25 funding opportunities

Pfizer announced positive topline results from the phase III TALAPRO-3 study of Talzenna (talazoparib), an oral poly ADP-ribose polymerase inhibitor, in combination with Xtandi (enzalutamide), an androgen receptor pathway inhibitor, in people with homologous recombination repair gene-mutated metastatic castration-sensitive prostate cancer, also known as metastatic hormone-sensitive prostate cancer.

A team of researchers engineered a new class of “turbocharged” T cells that may be stronger, longer-lasting, and more precise at killing prostate cancer cells. The approach represents a step toward developing safer, more effective T-cell therapies for prostate cancer and could potentially be adapted to treat a wide range of other tumors.